 Alector, Inc Nasdaq: ALEC is a clinical-stage biopharmaceutical company focused on immuno-neurology, immune dysfunction studies related to degenerative brain disorders. Alector has 4-clinical phase therapeutics entirely targeting primarily neurological diseases including Alzheimers and Frontotemporal Dementia. Alector also has 2-preclinical therapeutics, and 8 in the research phase. 